181 related articles for article (PubMed ID: 32098071)
1. PTEN Expression as a Complementary Biomarker for Mismatch Repair Testing in Breast Cancer.
Lopez G; Noale M; Corti C; Gaudioso G; Sajjadi E; Venetis K; Gambini D; Runza L; Costanza J; Pesenti C; Grossi F; Maggi S; Ferrero S; Bosari S; Fusco N
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32098071
[TBL] [Abstract][Full Text] [Related]
2. Mismatch Repair Protein Loss as a Prognostic and Predictive Biomarker in Breast Cancers Regardless of Microsatellite Instability.
Fusco N; Lopez G; Corti C; Pesenti C; Colapietro P; Ercoli G; Gaudioso G; Faversani A; Gambini D; Michelotti A; Despini L; Blundo C; Vaira V; Miozzo M; Ferrero S; Bosari S
JNCI Cancer Spectr; 2018 Oct; 2(4):pky056. PubMed ID: 31360876
[TBL] [Abstract][Full Text] [Related]
3. Combined analysis of PTEN, HER2, and hormone receptors status: remodeling breast cancer risk profiling.
Sajjadi E; Venetis K; Piciotti R; Gambini D; Blundo C; Runza L; Ferrero S; Guerini-Rocco E; Fusco N
BMC Cancer; 2021 Oct; 21(1):1152. PubMed ID: 34706703
[TBL] [Abstract][Full Text] [Related]
4. Association between mismatch repair gene and irinotecan-based chemotherapy in metastatic colon cancer.
Ma J; Zhang Y; Shen H; Kapesa L; Liu W; Zeng M; Zeng S
Tumour Biol; 2015 Dec; 36(12):9599-609. PubMed ID: 26142736
[TBL] [Abstract][Full Text] [Related]
5. DNA mismatch repair deficiency in breast carcinoma: a pilot study of triple-negative and non-triple-negative tumors.
Wen YH; Brogi E; Zeng Z; Akram M; Catalano J; Paty PB; Norton L; Shia J
Am J Surg Pathol; 2012 Nov; 36(11):1700-8. PubMed ID: 22992699
[TBL] [Abstract][Full Text] [Related]
6. High homogeneity of MMR deficiency in ovarian cancer.
Fraune C; Rosebrock J; Simon R; Hube-Magg C; Makrypidi-Fraune G; Kluth M; Büscheck F; Höflmayer D; Schmalfeldt B; Müller V; Wölber L; Witzel I; Paluchowski P; Wilke C; Heilenkötter U; von Leffern I; Clauditz TS; Wilczak W; Sauter G; Steurer S; Burandt E
Gynecol Oncol; 2020 Mar; 156(3):669-675. PubMed ID: 31924330
[TBL] [Abstract][Full Text] [Related]
7. Clinical Targeted Next-Generation Sequencing Shows Increased Mutational Load in Endometrioid-type Endometrial Adenocarcinoma With Deficient DNA Mismatch Repair.
Lee PJ; McNulty S; Duncavage EJ; Heusel JW; Hagemann IS
Int J Gynecol Pathol; 2018 Nov; 37(6):581-589. PubMed ID: 29084048
[TBL] [Abstract][Full Text] [Related]
8. Programmed death-ligand 1 expression in gastric cancer: correlation with mismatch repair deficiency and HER2-negative status.
Wang L; Zhang Q; Ni S; Tan C; Cai X; Huang D; Sheng W
Cancer Med; 2018 Jun; 7(6):2612-2620. PubMed ID: 29673110
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical expression of mismatch repair proteins (MSH2, MSH6, MLH1, and PMS2) in prostate cancer: correlation with grade groups (WHO 2016) and ERG and PTEN status.
Albero-González R; Hernández-Llodrà S; Juanpere N; Lorenzo M; Lloret A; Segalés L; Duran X; Fumadó L; Cecchini L; Lloreta-Trull J
Virchows Arch; 2019 Aug; 475(2):223-231. PubMed ID: 31209634
[TBL] [Abstract][Full Text] [Related]
10. Risk of secondary malignancy (including breast) in patients with mismatch-repair protein deficiency.
Clay MR; Allison KH; Folkins AK; Longacre TA
Am J Surg Pathol; 2014 Nov; 38(11):1494-500. PubMed ID: 24921635
[TBL] [Abstract][Full Text] [Related]
11. Role of HER2-Related Biomarkers (HER2, p95HER2, HER3, PTEN, and PIK3CA) in the Efficacy of Lapatinib plus Capecitabine in HER2-Positive Advanced Breast Cancer Refractory to Trastuzumab.
Nishimura R; Toh U; Tanaka M; Saimura M; Okumura Y; Saito T; Tanaka T; Teraoka M; Shimada K; Katayama K; Koga T; Kurashita K; Hasegawa S; Todoroki H; Kai Y; Ohi Y; Toyoshima S; Arima N; Mitsuyama S; Tamura K
Oncology; 2017; 93(1):51-61. PubMed ID: 28478451
[TBL] [Abstract][Full Text] [Related]
12. Accuracy of four mononucleotide-repeat markers for the identification of DNA mismatch-repair deficiency in solid tumors.
Takehara Y; Nagasaka T; Nyuya A; Haruma T; Haraga J; Mori Y; Nakamura K; Fujiwara T; Boland CR; Goel A
J Transl Med; 2018 Jan; 16(1):5. PubMed ID: 29329588
[TBL] [Abstract][Full Text] [Related]
13. Distinct Immunological Landscapes Characterize Inherited and Sporadic Mismatch Repair Deficient Endometrial Cancer.
Ramchander NC; Ryan NAJ; Walker TDJ; Harries L; Bolton J; Bosse T; Evans DG; Crosbie EJ
Front Immunol; 2019; 10():3023. PubMed ID: 31998307
[TBL] [Abstract][Full Text] [Related]
14. Distinct Clinicopathological Patterns of Mismatch Repair Status in Colorectal Cancer Stratified by KRAS Mutations.
Li W; Zhi W; Zou S; Qiu T; Ling Y; Shan L; Shi S; Ying J
PLoS One; 2015; 10(6):e0128202. PubMed ID: 26042813
[TBL] [Abstract][Full Text] [Related]
15. Association of tumor morphology with mismatch-repair protein status in older endometrial cancer patients: implications for universal versus selective screening strategies for Lynch syndrome.
Rabban JT; Calkins SM; Karnezis AN; Grenert JP; Blanco A; Crawford B; Chen LM
Am J Surg Pathol; 2014 Jun; 38(6):793-800. PubMed ID: 24503759
[TBL] [Abstract][Full Text] [Related]
16. Defective Mismatch Repair Status was not Associated with DFS and OS in Stage II Colon Cancer Treated with Adjuvant Chemotherapy.
Kim JE; Hong YS; Kim HJ; Kim KP; Lee JL; Park SJ; Lim SB; Park IJ; Kim CW; Yoon YS; Yu CS; Kim JC; Hoon KJ; Kim TW
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S630-7. PubMed ID: 26271397
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological and survival characteristic of mismatch repair status in ovarian clear cell carcinoma.
Zhu J; Ke G; Bi R; Wu X
J Surg Oncol; 2020 Sep; 122(3):538-546. PubMed ID: 32396667
[TBL] [Abstract][Full Text] [Related]
18. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.
Cohen R; Buhard O; Cervera P; Hain E; Dumont S; Bardier A; Bachet JB; Gornet JM; Lopez-Trabada D; Dumont S; Kaci R; Bertheau P; Renaud F; Bibeau F; Parc Y; Vernerey D; Duval A; Svrcek M; André T
Eur J Cancer; 2017 Nov; 86():266-274. PubMed ID: 29055842
[TBL] [Abstract][Full Text] [Related]
19. Tau and PTEN status as predictive markers for response to trastuzumab and paclitaxel in patients with HER2-positive breast cancer.
Koo DH; Lee HJ; Ahn JH; Yoon DH; Kim SB; Gong G; Son BH; Ahn SH; Jung KH
Tumour Biol; 2015 Aug; 36(8):5865-71. PubMed ID: 25725586
[TBL] [Abstract][Full Text] [Related]
20. A relationship to survival is seen by combining the factors of mismatch repair status, tumor location and age of onset in colorectal cancer patients.
Li P; Xiao Z; Braciak TA; Ou Q; Chen G; Oduncu FS
PLoS One; 2017; 12(3):e0172799. PubMed ID: 28253296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
